Search NLS News

The company’s collaborative project with Vecura at Karolinska University Hospital and Uppsala University has been awarded SEK 850,000 from the Center for Advanced Medical Products (CAMP). The purpose of the project is to develop an automated production process of CAR T-cells (ELC-401) for use in clinical studies. The production process will be developed in a […]

OssDsign has announced that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 % spinal fusion rate at 12 months as assessed with CT by independent radiological review from Medical Metrics Inc. after surgery with the novel nanosynthetic bone graft OssDsign Catalyst, states […]

Toleranzia has announced that the toxicology study, conducted under Good Laboratory Practice (GLP), to enable first-in-human clinical trials, has been completed. The drug candidate was well tolerated at the dose tested, a finding fully supporting continued development of TOL2 and the submission of an application for the initiation of clinical trials in patients with myasthenia […]

FluoGuide plans to expand the scope of application of FG001 and advance its development toward approval in aggressive brain cancer. FluoGuide has obtained clinical proof of concept of FG001, a fluorescent molecule targeting the cancer specific uPAR receptor, which lights up cancer cells to improve outcomes of surgery. This includes positive phase II data across […]

Charlotte Fribert (CF), CEO of Toleranzia, and Niranjan Sardesai (NS), founder and CEO of Geneos Therapeutics, were among the delegates partaking in the future of advanced biologics conference (September 2023) that already tried out the innovation hub approach for real. In a brief interview, Helena Strigård gathered some of their thoughts. The projects that your […]

In a small village, some hours north of Stockholm, a competence center and innovation hub for advanced biologics was inaugurated on the 27th of September. This did not pass unnoticed; quite the opposite.

Capitainer has announced the grant of three US patents for their soon to be launched plasma/serum separation device. “These patents reinforce our strategic position, facilitating Capitainer’s expansion in the US market. The recognition from the United States Patent Office is a testament to the technological advancements we’ve achieved. This enables us to extend our advanced […]

Qlucore has agreed a two-year license with Boehringer Ingelheim worth approximately SEK 1.67 million. The license enables global utilization of Qlucore Omics Explorer software, a software designed for research in pharmaceuticals and biotechnology, catering to both commercial and academic users. Through interactive visualization coupled with rapid calculations, users can identify crucial information within often vast […]

For the past decade Danish Genmab has experienced rapid growth and become an integrated biotech innovation powerhouse with a strong international footprint. NLS asked Birgitte Stephensen, Executive Vice President, Chief Legal Officer & Site Lead at Genmab in the Valby district of Copenhagen, about her company’s journey, its growth and its future plans. Genmab was […]

Norway is home to impressive research environments that produce groundbreaking work in several areas. One of the strongholds lies within the field of immunology. This is an area where Norway truly has a long tradition, a scientific and industrial track record, and the potential to become a driving force not just for groundbreaking research but […]